Announcements Trials
Browse Landscape

Phase

Phase 1/2 4Phase 2 3Phase 1 3Phase 3 2Phase NA 1

Status

Completed 3Recruiting 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 1Lymphoid 1Gynecologic 1Gastrointestinal 1

Conditions

Small Cell Lung Carcinoma 1Recurrence 1Ovarian Neoplasms 1Lymphoma, Non-Hodgkin 1Carcinoma, Hepatocellular 1

Interventions

pembrolizumab 242Carboplatin 137Nivolumab 132Gemcitabine 127Paclitaxel 116Cisplatin 105Cyclophosphamide 97Bevacizumab 93Dexamethasone 78Injections 75Pemetrexed 71Docetaxel 71Fluorouracil 68Capecitabine 65Rituximab 61Cetuximab 61atezolizumab 59130-nm albumin-bound paclitaxel 59Oxaliplatin 58Leucovorin 57Ipilimumab 54fludarabine 50Lenalidomide 47Azacitidine 40Irinotecan 39venetoclax 38Fulvestrant 38Albumin-Bound Paclitaxel 36Prednisone 35Trastuzumab 34

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1/2 × INDUSTRY × chiauranib × Clear all
NCT05271292 2024-07-16

SCLC

Chipscreen Biosciences, Ltd.

Phase 1/2 Recruiting
36 enrolled
Thoracic

Small Cell Lung Carcinoma

NCT03974243 2022-03-09

Chiauranib in Combination With Chidamide in Patients With Relapsed/Refractory Non-Hodgkin's Lymphoma

Chipscreen Biosciences, Ltd.

Phase 1/2 Completed
9 enrolled
Lymphoid

Lymphoma, Non-Hodgkin

NCT03245190 2021-06-18

Study of Chiauranib in Patients With Advanced Hepatocellular Carcinoma

Chipscreen Biosciences, Ltd.

Phase 1/2 Completed
27 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT03166891 2020-01-18

Phase Ib Study of Chiauranib in Patients With Ovarian Cancer

Chipscreen Biosciences, Ltd.

Phase 1/2 Completed
25 enrolled
Gynecologic

Ovarian Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡